MedTrace Logo

Telomerase Activator and Retinal Amyloid

NCT02530255 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-07-05

No results posted yet for this study

Summary

A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease.

Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

cycloastragenol

Oral telomerase activator - cycloastragenol.

DIETARY_SUPPLEMENT

placebo (for cycloastragenol)

placebo comparator, placebo for cycloastragenol.

Sponsors & Collaborators

  • TA-Sciences

    collaborator UNKNOWN

  • Chippewa Valley Eye Clinic

    lead OTHER

Principal Investigators

  • Coad T. Dow, M.D. · Chippewa Valley Eye Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2018-10-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02530255 on ClinicalTrials.gov